Evidence map›Paper›PMID 29730586›Full record

ArticleThe International journal on drug policy2018

Overlap between harm reduction and HIV service utilisation among PWID in India: Implications for HIV combination prevention.

M Kumi Smith, Sunil S Solomon, Derek A T Cummings, Aylur K Srikrishnan, M Suresh Kumar, C K Vasudevan, Allison M McFall, Gregory M Lucas, David D Celentano, Shruti H Mehta

Abstract read
In one paragraph

Article in The International journal on drug policy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

M Kumi SmithJohns Hopkins University Bloomberg School of Public Health,615 N Wolfe Street, Baltimore, MD, USA; University of North Carolina at Chapel Hill School of Medicine, 130 Mason Farm Road, Chapel Hill, NC, USA. Electronic address: kumi.smith@unc.edu.
Sunil S SolomonJohns Hopkins University School of Medicine, 733 N Broadway, Baltimore, MD 21205, USA. Electronic address: sss@jhmi.edu.
Derek A T CummingsEmerging Pathogens Institute, University of Florida at Gainesville, Gainesville, USA. Electronic address: datc@ufl.edu.
Aylur K SrikrishnanY.R. Gaitonde Centre for AIDS Research and Education, Chennai, Tamil Nadu, India. Electronic address: krish@yrgcare.org.
M Suresh KumarY.R. Gaitonde Centre for AIDS Research and Education, Chennai, Tamil Nadu, India. Electronic address: msuresh1955@gmail.com.
C K VasudevanY.R. Gaitonde Centre for AIDS Research and Education, Chennai, Tamil Nadu, India. Electronic address: vasu@yrgcare.org.
Allison M McFallJohns Hopkins University Bloomberg School of Public Health,615 N Wolfe Street, Baltimore, MD, USA. Electronic address: amcfall2@jhu.edu.
Gregory M LucasJohns Hopkins University School of Medicine, 733 N Broadway, Baltimore, MD 21205, USA. Electronic address: glucas@jhmi.edu.
David D CelentanoJohns Hopkins University Bloomberg School of Public Health,615 N Wolfe Street, Baltimore, MD, USA. Electronic address: dcelent1@jhu.edu.
Shruti H MehtaJohns Hopkins University Bloomberg School of Public Health,615 N Wolfe Street, Baltimore, MD, USA. Electronic address: shmehta@jhsph.edu.
Johns Hopkins University · USYR Gaitonde Centre for AIDS Research and Education · INUniversity of Florida · USUniversity of North Carolina at Chapel Hill · US

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
Strategies to improve the HIV care continuum among key populations in IndiaR01DA041034 · NIDA · JOHNS HOPKINS UNIVERSITY · PI LUCAS, GREGORY M, MEHTA, SHRUTI H · 2015 to 2021
$6.7M
Integrated Care Clinics for IDUs in India: a cluster randomized trialR01DA032059 · NIDA · JOHNS HOPKINS UNIVERSITY · PI LUCAS, GREGORY M, MEHTA, SHRUTI H · 2011 to 2015
$6.3M
Johns Hopkins HIV Epidemiology and Prevention Sciences Training ProgramT32AI102623 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Shruti H Mehta · 2013 to 2026
$5.3M
Preventing HIV Infection Among MSM in Southern IndiaR01MH089266 · NIMH · JOHNS HOPKINS UNIVERSITY · PI CELENTANO, DAVID D. · 2010 to 2015
$2.9M
Treatment outcomes and comorbidity in HIV-infected IDUK24DA035684 · NIDA · JOHNS HOPKINS UNIVERSITY · PI LUCAS, GREGORY M · 2014 to 2024
$1.5M
Modeling interactions between HIV interventions in key populations in IndiaR21AI116296 · NIAID · UNIVERSITY OF FLORIDA · PI CUMMINGS, DEREK A · 2015 to 2016
$450k
Investigating the Potential of Respondent-Driven Sampling to Reach Undiagnosed, Out-of-Care HIV-infected People Who Inject DrugsF31DA044046 · NIDA · JOHNS HOPKINS UNIVERSITY · PI MCFALL, ALLISON MARIE · 2017 to 2018
$78k
NIAID NIH HHS P30 AI094189NIAID NIH HHS R21 AI116296NIAID NIH HHS T32 AI102623NIDA NIH HHS F31 DA044046NIDA NIH HHS K24 DA035684NIDA NIH HHS R01 DA032059NIDA NIH HHS R01 DA041034NIMH NIH HHS R01 MH089266
6 · The paper itself

Abstract

backgroundIn some regions, HIV incidence is rising among people who inject drugs (PWID). Combination prevention approaches are well suited to PWID who face multiple sources of HIV risk. This analysis investigates patterns of utilisation to basic HIV services (HIV counselling and testing [HCT], antiretroviral therapy [ART]) as well as harm reduction programs (needle and syringe exchange programs [NSEP] and opioid agonist therapy [OAT]) among PWID and how utilisation of harm reduction services is associated with HIV-related care seeking behaviours.

methodsRespondent-driven sampling was used to recruit 14,481 PWID across 15 cities in India. Sampling-weighted multilevel logistic regression models assessed associations between utilisation of harm reduction service and HCT and ART use among those indicated (90.3% and 5.0% of full sample, respectively). We considered both recent (prior year) and ever use of services.

resultsOverall, 42.3% reported prior HIV testing and 57.9% of eligible persons reported ART initiation, but overlap with NSEP and OAT use was limited. In adjusted models, recent and ever use of both NSEP and OAT were significantly associated with recent and ever HCT utilisation, respectively; however, harm reduction utilisation was not associated with ART initiation among eligible participants.

conclusionsHarm reduction services may play a key role in linking PWID with HIV testing; however, they were not associated with ART initiation among eligible individuals. Moreover, a large majority who utilised NSEP and OAT were not engaged in optimal HIV care or prevention, highlighting missed opportunities and a need for stronger linkages between NSEP/OAT and HIV care and treatment, particularly among those actively injecting. These findings provide key insights to better understand how services can be linked or combined to optimise service utilisation among PWID.

Indexed as

Harm ReductionPatient Acceptance of Health CareAdultFemaleHIV InfectionsHumansMaleSubstance Abuse, IntravenousYoung AdultHarm reductionHIVIndiaInjection drug use

Identifiers

PMID29730586
PMCPMC6430979
OpenAlexW2802843987

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.